Search

Your search keyword '"Gladman, Dafna D"' showing total 194 results
Start Over Author "Gladman, Dafna D" Journal annals of the rheumatic diseases
194 results on '"Gladman, Dafna D"'

1. Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Author

Choi, May Yee, Clarke, Ann Elaine, Urowitz, Murray, Hanly, John, St-Pierre, Yvan, Gordon, Caroline, Bae, Sang-Cheol, Romero-Diaz, Juanita, Sanchez-Guerrero, Jorge, Bernatsky, Sasha, Wallace, Daniel J, Isenberg, David, Rahman, Anisur, Merrill, Joan T, Fortin, Paul R, Gladman, Dafna D, Bruce, Ian N, Petri, Michelle, Ginzler, Ellen M, Dooley, Mary Anne, Ramsey-Goldman, Rosalind, Manzi, Susan, Jönsen, Andreas, Alarcón, Graciela S, van Vollenhoven, Ronald F, Aranow, Cynthia, Mackay, Meggan, Ruiz-Irastorza, Guillermo, Lim, Sam, Inanc, Murat, Kalunian, Ken, Jacobsen, Søren, Peschken, Christine, Kamen, Diane L, Askanase, Anca, Buyon, Jill P, Costenbader, Karen H, and Fritzler, Marvin J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Autoimmune Disease, Lupus, Antibodies, Antinuclear, Autoantibodies, Cross-Sectional Studies, Fluorescent Antibody Technique, Indirect, Humans, Lupus Erythematosus, Systemic, Systemic Lupus Erythematosus, Autoimmunity, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectivesA perception derived from cross-sectional studies of small systemic lupus erythematosus (SLE) cohorts is that there is a marked discrepancy between antinuclear antibody (ANA) assays, which impacts on clinicians' approach to diagnosis and follow-up. We compared three ANA assays in a longitudinal analysis of a large international incident SLE cohort retested regularly and followed for 5 years.MethodsDemographic, clinical and serological data was from 805 SLE patients at enrolment, year 3 and 5. Two HEp-2 indirect immunofluorescence assays (IFA1, IFA2), an ANA ELISA, and SLE-related autoantibodies were performed in one laboratory. Frequencies of positivity, titres or absorbance units (AU), and IFA patterns were compared using McNemar, Wilcoxon and kappa statistics, respectively.ResultsAt enrolment, ANA positivity (≥1:80) was 96.1% by IFA1 (median titre 1:1280 (IQR 1:640-1:5120)), 98.3% by IFA2 (1:2560 (IQR 1:640-1:5120)) and 96.6% by ELISA (176.3 AU (IQR 106.4 AU-203.5 AU)). At least one ANA assay was positive for 99.6% of patients at enrolment. At year 5, ANA positivity by IFAs (IFA1 95.2%; IFA2 98.9%) remained high, while there was a decrease in ELISA positivity (91.3%, p91% agreement in ANA positivity at all time points and ≥71% agreement in IFA patterns between IFA1 and IFA2.ConclusionIn recent-onset SLE, three ANA assays demonstrated commutability with a high proportion of positivity and titres or AU. However, over 5 years follow-up, there was modest variation in ANA assay performance. In clinical situations where the SLE diagnosis is being considered, a negative test by either the ELISA or HEp-2 IFA may require reflex testing.

Published
2022

2. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

Author

Almeida-Brasil, Celline C, Hanly, John G, Urowitz, Murray, Clarke, Ann Elaine, Ruiz-Irastorza, Guillermo, Gordon, Caroline, Ramsey-Goldman, Rosalind, Petri, Michelle, Ginzler, Ellen M, Wallace, DJ, Bae, Sang-Cheol, Romero-Diaz, Juanita, Dooley, Mary Anne, Peschken, Christine, Isenberg, David, Rahman, Anisur, Manzi, Susan, Jacobsen, Søren, Lim, Sam, van Vollenhoven, Ronald F, Nived, Ola, Jönsen, Andreas, Kamen, Diane L, Aranow, Cynthia, Sanchez-Guerrero, Jorge, Gladman, Dafna D, Fortin, Paul R, Alarcón, Graciela S, Merrill, Joan T, Kalunian, Kenneth, Ramos-Casals, Manuel, Steinsson, Kristján, Zoma, Asad, Askanase, Anca, Khamashta, Munther A, Bruce, Ian N, Inanc, Murat, Abrahamowicz, Michal, and Bernatsky, Sasha

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Lupus, Autoimmune Disease, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Antirheumatic Agents, Drug Tapering, Female, Follow-Up Studies, Humans, Hydroxychloroquine, Lupus Erythematosus, Systemic, Male, Middle Aged, Prospective Studies, Symptom Flare Up, Treatment Outcome, autoimmune diseases, epidemiology, hydroxychloroquine, systemic lupus erythematosus, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectivesTo evaluate systemic lupus erythematosus (SLE) flares following hydroxychloroquine (HCQ) reduction or discontinuation versus HCQ maintenance.MethodsWe analysed prospective data from the Systemic Lupus International Collaborating Clinics (SLICC) cohort, enrolled from 33 sites within 15 months of SLE diagnosis and followed annually (1999-2019). We evaluated person-time contributed while on the initial HCQ dose ('maintenance'), comparing this with person-time contributed after a first dose reduction, and after a first HCQ discontinuation. We estimated time to first flare, defined as either subsequent need for therapy augmentation, increase of ≥4 points in the SLE Disease Activity Index-2000, or hospitalisation for SLE. We estimated adjusted HRs (aHRs) with 95% CIs associated with reducing/discontinuing HCQ (vs maintenance). We also conducted separate multivariable hazard regressions in each HCQ subcohort to identify factors associated with flare.ResultsWe studied 1460 (90% female) patients initiating HCQ. aHRs for first SLE flare were 1.20 (95% CI 1.04 to 1.38) and 1.56 (95% CI 1.31 to 1.86) for the HCQ reduction and discontinuation groups, respectively, versus HCQ maintenance. Patients with low educational level were at particular risk of flaring after HCQ discontinuation (aHR 1.43, 95% CI 1.09 to 1.87). Prednisone use at time-zero was associated with over 1.5-fold increase in flare risk in all HCQ subcohorts.ConclusionsSLE flare risk was higher after HCQ taper/discontinuation versus HCQ maintenance. Decisions to maintain, reduce or stop HCQ may affect specific subgroups differently, including those on prednisone and/or with low education. Further study of special groups (eg, seniors) may be helpful.

Published
2022

3. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

Author

Smolen, Josef S, Schöls, Monika, Braun, Jürgen, Dougados, Maxime, FitzGerald, Oliver, Gladman, Dafna D, Kavanaugh, Arthur, Landewé, Robert, Mease, Philip, Sieper, Joachim, Stamm, Tanja, Wit, Maarten de, Aletaha, Daniel, Baraliakos, Xenofon, Betteridge, Neil, Bosch, Filip van den, Coates, Laura C, Emery, Paul, Gensler, Lianne S, Gossec, Laure, Helliwell, Philip, Jongkees, Merryn, Kvien, Tore K, Inman, Robert D, McInnes, Iain B, Maccarone, Mara, Machado, Pedro M, Molto, Anna, Ogdie, Alexis, Poddubnyy, Denis, Ritchlin, Christopher, Rudwaleit, Martin, Tanew, Adrian, Thio, Bing, Veale, Douglas, Vlam, Kurt de, and van der Heijde, Désirée

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Arthritis, Autoimmune Disease, Clinical Research, Rare Diseases, Inflammatory and immune system, Advisory Committees, Arthritis, Psoriatic, Axis, Cervical Vertebra, Consensus, Decision Making, Humans, Severity of Illness Index, Spondylitis, Ankylosing, Ankylosing Spondylitis, Outcomes Research, Psoriatic Arthritis, Spondyloarthritis, Treatment, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field.

Published
2018

4. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

Author

Fanouriakis, Antonis, primary, Kostopoulou, Myrto, additional, Andersen, Jeanette, additional, Aringer, Martin, additional, Arnaud, Laurent, additional, Bae, Sang-Cheol, additional, Boletis, John, additional, Bruce, Ian N, additional, Cervera, Ricard, additional, Doria, Andrea, additional, Dörner, Thomas, additional, Furie, Richard A, additional, Gladman, Dafna D, additional, Houssiau, Frederic A, additional, Inês, Luís Sousa, additional, Jayne, David, additional, Kouloumas, Marios, additional, Kovács, László, additional, Mok, Chi Chiu, additional, Morand, Eric F, additional, Moroni, Gabriella, additional, Mosca, Marta, additional, Mucke, Johanna, additional, Mukhtyar, Chetan B, additional, Nagy, György, additional, Navarra, Sandra, additional, Parodis, Ioannis, additional, Pego-Reigosa, José M, additional, Petri, Michelle, additional, Pons-Estel, Bernardo A, additional, Schneider, Matthias, additional, Smolen, Josef S, additional, Svenungsson, Elisabet, additional, Tanaka, Yoshiya, additional, Tektonidou, Maria G, additional, Teng, YK Onno, additional, Tincani, Angela, additional, Vital, Edward M, additional, van Vollenhoven, Ronald F, additional, Wincup, Chris, additional, Bertsias, George, additional, and Boumpas, Dimitrios T, additional

Published
2023
Full Text
View/download PDF

5. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Author

Bruce, Ian N, O'Keeffe, Aidan G, Farewell, Vern, Hanly, John G, Manzi, Susan, Su, Li, Gladman, Dafna D, Bae, Sang-Cheol, Sanchez-Guerrero, Jorge, Romero-Diaz, Juanita, Gordon, Caroline, Wallace, Daniel J, Clarke, Ann E, Bernatsky, Sasha, Ginzler, Ellen M, Isenberg, David A, Rahman, Anisur, Merrill, Joan T, Alarcón, Graciela S, Fessler, Barri J, Fortin, Paul R, Petri, Michelle, Steinsson, Kristjan, Dooley, Mary Anne, Khamashta, Munther A, Ramsey-Goldman, Rosalind, Zoma, Asad A, Sturfelt, Gunnar K, Nived, Ola, Aranow, Cynthia, Mackay, Meggan, Ramos-Casals, Manuel, van Vollenhoven, Ronald F, Kalunian, Kenneth C, Ruiz-Irastorza, Guillermo, Lim, Sam, Kamen, Diane L, Peschken, Christine A, Inanc, Murat, and Urowitz, Murray B

Subjects
Autoimmune Disease, Lupus, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Inflammatory and immune system, Good Health and Well Being, Adult, Cohort Studies, Disease Progression, Ethnicity, Female, Health Status, Humans, Kaplan-Meier Estimate, Longitudinal Studies, Lupus Erythematosus, Systemic, Male, Middle Aged, Proportional Hazards Models, Prospective Studies, Quality of Life, Young Adult, Corticosteroids, Inflammation, Outcomes research, Systemic Lupus Erythematosus, Clinical Sciences, Immunology, Public Health and Health Services, Arthritis & Rheumatology
Abstract

Background and aimsWe studied damage accrual and factors determining development and progression of damage in an international cohort of systemic lupus erythematosus (SLE) patients.MethodsThe Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort recruited patients within 15 months of developing four or more 1997 American College of Rheumatology (ACR) criteria for SLE; the SLICC/ACR damage index (SDI) was measured annually. We assessed relative rates of transition using maximum likelihood estimation in a multistate model. The Kaplan-Meier method estimated the probabilities for time to first increase in SDI score and Cox regression analysis was used to assess mortality.ResultsWe recruited 1722 patients; mean (SD) age 35.0 (13.4) years at cohort entry. Patients with damage at enrolment were more likely to have further worsening of SDI (SDI 0 vs ≥1; p

Published
2015

6. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort

Author

Parker, Ben, Urowitz, Murray B, Gladman, Dafna D, Lunt, Mark, Donn, Rachelle, Bae, Sang-Cheol, Sanchez-Guerrero, Jorge, Romero-Diaz, Juanita, Gordon, Caroline, Wallace, Daniel J, Clarke, Ann E, Bernatsky, Sasha, Ginzler, Ellen M, Isenberg, David A, Rahman, Anisur, Merrill, Joan T, Alarcón, Graciela S, Fessler, Barri J, Fortin, Paul R, Hanly, John G, Petri, Michelle, Steinsson, Kristjan, Dooley, Mary Anne, Manzi, Susan, Khamashta, Munther A, Ramsey-Goldman, Rosalind, Zoma, Asad A, Sturfelt, Gunnar K, Nived, Ola, Aranow, Cynthia, Mackay, Meggan, Ramos-Casals, Manuel, van Vollenhoven, Ronald F, Kalunian, Kenneth C, Ruiz-Irastorza, Guillermo, Lim, S Sam, Kamen, Diane L, Peschken, Christine A, Inanc, Murat, and Bruce, Ian N

Subjects
Clinical Research, Lupus, Autoimmune Disease, Kidney Disease, Prevention, Cardiovascular, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Inflammatory and immune system, Good Health and Well Being, Adult, Cohort Studies, Comorbidity, Female, Humans, Logistic Models, Lupus Erythematosus, Systemic, Male, Metabolic Syndrome, Middle Aged, Phenotype, Prevalence, Young Adult, Cardiovascular Disease, Inflammation, Systemic Lupus Erythematosus, Clinical Sciences, Immunology, Public Health and Health Services, Arthritis & Rheumatology
Abstract

BackgroundThe metabolic syndrome (MetS) may contribute to the increased cardiovascular risk in systemic lupus erythematosus (SLE). We examined the association between MetS and disease activity, disease phenotype and corticosteroid exposure over time in patients with SLE.MethodsRecently diagnosed (1, higher disease activity, increasing age and Hispanic or Black African race/ethnicity were independently associated with MetS over the first 2 years of follow-up in the cohort.ConclusionsMetS is a persistent phenotype in a significant proportion of patients with SLE. Renal lupus, active inflammatory disease and damage are SLE-related factors that drive MetS development while antimalarial agents appear to be protective from early in the disease course.

Published
2015

7. Lymphoma risk in systemic lupus: effects of disease activity versus treatment.

Author

Bernatsky, Sasha, Ramsey-Goldman, Rosalind, Joseph, Lawrence, Boivin, Jean-Francois, Costenbader, Karen H, Urowitz, Murray B, Gladman, Dafna D, Fortin, Paul R, Nived, Ola, Petri, Michelle A, Jacobsen, Soren, Manzi, Susan, Ginzler, Ellen M, Isenberg, David, Rahman, Anisur, Gordon, Caroline, Ruiz-Irastorza, Guillermo, Yelin, Edward, Bae, Sang-Cheol, Wallace, Daniel J, Peschken, Christine A, Dooley, Mary Anne, Edworthy, Steven M, Aranow, Cynthia, Kamen, Diane L, Romero-Diaz, Juanita, Askanase, Anca, Witte, Torsten, Barr, Susan G, Criswell, Lindsey A, Sturfelt, Gunnar K, Blanco, Irene, Feldman, Candace H, Dreyer, Lene, Patel, Neha M, St Pierre, Yvan, and Clarke, Ann E

Subjects
Humans, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lupus Erythematosus, Systemic, Mycophenolic Acid, Cyclophosphamide, Methotrexate, Azathioprine, Immunosuppressive Agents, Glucocorticoids, Antimalarials, Risk Factors, Case-Control Studies, Adult, Middle Aged, Female, Male, Young Adult, Disease Activity, Epidemiology, Systemic Lupus Erythematosus, Treatment, Rare Diseases, Lupus, Hematology, Clinical Research, Cancer, Prevention, Lymphoma, Autoimmune Disease, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Inflammatory and immune system, Good Health and Well Being, Clinical Sciences, Immunology, Public Health and Health Services, Arthritis & Rheumatology
Abstract

ObjectiveTo examine disease activity versus treatment as lymphoma risk factors in systemic lupus erythematosus (SLE).MethodsWe performed case-cohort analyses within a multisite SLE cohort. Cancers were ascertained by regional registry linkages. Adjusted HRs for lymphoma were generated in regression models, for time-dependent exposures to immunomodulators (cyclophosphamide, azathioprine, methotrexate, mycophenolate, antimalarial drugs, glucocorticoids) demographics, calendar year, Sjogren's syndrome, SLE duration and disease activity. We used adjusted mean SLE Disease Activity Index scores (SLEDAI-2K) over time, and drugs were treated both categorically (ever/never) and as estimated cumulative doses.ResultsWe studied 75 patients with lymphoma (72 non-Hodgkin, three Hodgkin) and 4961 cancer-free controls. Most lymphomas were of B-cell origin. As is seen in the general population, lymphoma risk in SLE was higher in male than female patients and increased with age. Lymphomas occurred a mean of 12.4 years (median 10.9) after SLE diagnosis. Unadjusted and adjusted analyses failed to show a clear association of disease activity with lymphoma risk. There was a suggestion of greater exposure to cyclophosphamide and to higher cumulative steroids in lymphoma cases than the cancer-free controls.ConclusionsIn this large SLE sample, there was a suggestion of higher lymphoma risk with exposure to cyclophosphamide and high cumulative steroids. Disease activity itself was not clearly associated with lymphoma risk. Further work will focus on genetic profiles that might interact with medication exposure to influence lymphoma risk in SLE.

Published
2014

8. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.

Author

Fanouriakis, Antonis, Kostopoulou, Myrto, Andersen, Jeanette, Aringer, Martin, Arnaud, Laurent, Bae, Sang- Cheol, Boletis, John, Bruce, Ian N., Cervera, Ricard, Dörner, Andrea Doria Thomas, Furie, Richard A., Gladman, Dafna D., Houssiau, Frederic A., Inês, Luís Sousa, Jayne, David, Kouloumas, Marios, Kovács, László, Mok, Chi Chiu, Morand, Eric F., and Moroni, Gabriella

Published
2024
Full Text
View/download PDF

9. Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic Challenge (SWITCH): The Systemic Lupus International Collaborating Clinics experience

Author

Lee, Joo-Young E, primary, Mendel, Arielle, additional, Askanase, Anca, additional, Bae, Sang-Cheol, additional, Buyon, Jill P, additional, Clarke, Ann Elaine, additional, Costedoat-Chalumeau, Nathalie, additional, Fortin, Paul R, additional, Gladman, Dafna D, additional, Ramsey-Goldman, Rosalind, additional, Hanly, John G, additional, Inanç, Murat, additional, Isenberg, David Alan, additional, Mak, Anselm, additional, Mosca, Marta, additional, Petri, Michelle, additional, Rahman, Anisur, additional, Sanchez-Guerrero, Jorge, additional, Urowitz, Murray, additional, Wallace, Daniel J, additional, Bernatsky, Sasha, additional, and Vinet, Évelyne, additional

Published
2023
Full Text
View/download PDF

10. Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes

Author

Choi, May Yee, primary, Chen, Irene, additional, Clarke, Ann Elaine, additional, Fritzler, Marvin J, additional, Buhler, Katherine A, additional, Urowitz, Murray, additional, Hanly, John, additional, St-Pierre, Yvan, additional, Gordon, Caroline, additional, Bae, Sang-Cheol, additional, Romero-Diaz, Juanita, additional, Sanchez-Guerrero, Jorge, additional, Bernatsky, Sasha, additional, Wallace, Daniel J, additional, Isenberg, David Alan, additional, Rahman, Anisur, additional, Merrill, Joan T, additional, Fortin, Paul R, additional, Gladman, Dafna D, additional, Bruce, Ian N, additional, Petri, Michelle, additional, Ginzler, Ellen M, additional, Dooley, Mary Anne, additional, Ramsey-Goldman, Rosalind, additional, Manzi, Susan, additional, Jönsen, Andreas, additional, Alarcón, Graciela S, additional, van Vollenhoven, Ronald F, additional, Aranow, Cynthia, additional, Mackay, Meggan, additional, Ruiz-Irastorza, Guillermo, additional, Lim, Sam, additional, Inanc, Murat, additional, Kalunian, Kenneth, additional, Jacobsen, Søren, additional, Peschken, Christine, additional, Kamen, Diane L, additional, Askanase, Anca, additional, Buyon, Jill P, additional, Sontag, David, additional, and Costenbader, Karen H, additional

Published
2023
Full Text
View/download PDF

12. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

Author

Ugarte-Gil, Manuel Francisco, primary, Hanly, John, additional, Urowitz, Murray, additional, Gordon, Caroline, additional, Bae, Sang-Cheol, additional, Romero-Diaz, Juanita, additional, Sanchez-Guerrero, Jorge, additional, Bernatsky, Sasha, additional, Clarke, Ann Elaine, additional, Wallace, Daniel J, additional, Isenberg, David Alan, additional, Rahman, Anisur, additional, Merrill, Joan T, additional, Fortin, Paul R, additional, Gladman, Dafna D, additional, Bruce, Ian N, additional, Petri, Michelle, additional, Ginzler, Ellen M, additional, Dooley, Mary Anne, additional, Ramsey-Goldman, Rosalind, additional, Manzi, Susan, additional, Jönsen, Andreas, additional, van Vollenhoven, Ronald F, additional, Aranow, Cynthia, additional, Mackay, Meggan, additional, Ruiz-Irastorza, Guillermo, additional, Lim, Sam, additional, Inanc, Murat, additional, Kalunian, Ken, additional, Jacobsen, Søren, additional, Peschken, Christine, additional, Kamen, Diane L, additional, Askanase, Anca, additional, Pons-Estel, Bernardo A, additional, and Alarcón, Graciela S, additional

Published
2022
Full Text
View/download PDF

13. Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Braun and Landewé

Author

Gladman, Dafna D, primary, Mease, Philip J, additional, Bird, Paul, additional, Soriano, Enrique R, additional, Chakravarty, Soumya D, additional, Shawi, May, additional, Lavie, Frederic, additional, Gong, Cinty, additional, Leibowitz, Evan, additional, Poddubnyy, Denis, additional, Tam, Lai-Shan, additional, Helliwell, Philip S, additional, Kavanaugh, Arthur, additional, Deodhar, Atul A, additional, Østergaard, Mikkel, additional, and Baraliakos, Xenofon, additional

Published
2022
Full Text
View/download PDF

16. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

Author

Mease, Philip J, van der Heijde, Désirée, Ritchlin, Christopher T, Okada, Masato, Cuchacovich, Raquel S, Shuler, Catherine L, Lin, Chen-Yen, Braun, Daniel K, Lee, Chin H, Gladman, Dafna D, Barkham, N, Bessette, L, Alonso, R Blanco, Box, EJ, Brooks, M, Vargas, R Burgos, Chandran, V, Dhar, R, Nebro, A Fernandez, Fleischmann, R, Flint, K, Forstot, J, Villegas, F Galvan, Garcia-Fructuoso, F, Garmish, O, Geneva-Popova, M, Geusens, P, Gladstein, G, Goto, H, Griep, E, Harrell, R, Hou, A, Howell, M, Kivitz, A, Klein, S, Kolczewska, A, Korkosz, M, Montilla, D Lopez, Lue, C, Makino, Y, de la Fuente, JL Marenco, Marzo-Ortega, H, Miyamura, T, Mueller, E, Myasoutova, L, Sarabia, F Navarro, Ostor, A, Papp, K, Podrazilova, L, Pulka, G, Raussi, E-K, Rosa, J, Roussou, E, Rychlewska-Hanczewska, A, Sada, K, Sedova, L, Sikes, D, Solomon, S, Stack, M, Stanislavchuk, M, Suzuki, K, Tahir, H, Tälli, J, Toncheva, A, Turkiewicz, A, Valter, I, Vladeva, S, Wolfe, S, and Zyablova, N

Published
2017
Full Text
View/download PDF

17. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

Author

Almeida-Brasil, Celline C, primary, Hanly, John G, additional, Urowitz, Murray, additional, Clarke, Ann Elaine, additional, Ruiz-Irastorza, Guillermo, additional, Gordon, Caroline, additional, Ramsey-Goldman, Rosalind, additional, Petri, Michelle, additional, Ginzler, Ellen M, additional, Wallace, D J, additional, Bae, Sang-Cheol, additional, Romero-Diaz, Juanita, additional, Dooley, Mary Anne, additional, Peschken, Christine, additional, Isenberg, David, additional, Rahman, Anisur, additional, Manzi, Susan, additional, Jacobsen, Søren, additional, Lim, Sam, additional, van Vollenhoven, Ronald F, additional, Nived, Ola, additional, Jönsen, Andreas, additional, Kamen, Diane L, additional, Aranow, Cynthia, additional, Sanchez-Guerrero, Jorge, additional, Gladman, Dafna D, additional, Fortin, Paul R, additional, Alarcón, Graciela S, additional, Merrill, Joan T, additional, Kalunian, Kenneth, additional, Ramos-Casals, Manuel, additional, Steinsson, Kristján, additional, Zoma, Asad, additional, Askanase, Anca, additional, Khamashta, Munther A, additional, Bruce, Ian N, additional, Inanc, Murat, additional, Abrahamowicz, Michal, additional, and Bernatsky, Sasha, additional

Published
2021
Full Text
View/download PDF

20. ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients

Author

Robinson, Philip C, Costello, Mary-Ellen, Leo, Paul, Bradbury, Linda A, Hollis, Kelly, Cortes, Adrian, Lee, Seunghun, Joo, Kyung Bin, Shim, Seung-Cheol, Weisman, Michael, Ward, Michael, Zhou, Xiaodong, Garchon, Henri-Jean, Chiocchia, Gilles, Nossent, Johannes, Lie, Benedicte A, Førre, Øystein, Tuomilehto, Jaakko, Laiho, Kari, Jiang, Lei, Liu, Yu, Wu, Xin, Elewaut, Dirk, Burgos-Vargas, Ruben, Gensler, Lianne S, Stebbings, Simon, Haroon, Nigil, Mulero, Juan, Fernandez-Sueiro, Jose Luis, Gonzalez-Gay, Miguel A, Lopez-Larrea, Carlos, Bowness, Paul, Gafney, Karl, Gaston, John S Hill, Gladman, Dafna D, Rahman, Proton, Maksymowych, Walter P, Xu, Huji, van der Horst-Bruinsma, Irene E, Chou, Chung-Tei, Valle-Oñate, Raphael, Romero-Sánchez, María Consuelo, Hansen, Inger Myrnes, Pimentel-Santos, Fernando M, Inman, Robert D, Martin, Javier, Breban, Maxime, Evans, David, Reveille, John D, Kim, Tae-Hwan, Wordsworth, B Paul, and Brown, Matthew A

Published
2015
Full Text
View/download PDF

22. Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.

Author

May Yee Choi, Clarke, Ann Elaine, Urowitz, Murray, Hanly, John, St-Pierre, Yvan, Gordon, Caroline, Sang-Cheol Bae, Romero-Diaz, Juanita, Sanchez-Guerrero, Jorge, Bernatsky, Sasha, Wallace, Daniel J., Isenberg, David, Rahman, Anisur, Merrill, Joan T., Fortin, Paul R., Gladman, Dafna D., Bruce, Ian N., Petri, Michelle, Ginzler, Ellen M., and Dooley, Mary Anne

Abstract

Objectives: A perception derived from cross-sectional studies of small systemic lupus erythematosus (SLE) cohorts is that there is a marked discrepancy between antinuclear antibody (ANA) assays, which impacts on clinicians' approach to diagnosis and follow-up. We compared three ANA assays in a longitudinal analysis of a large international incident SLE cohort retested regularly and followed for 5 years.Methods: Demographic, clinical and serological data was from 805 SLE patients at enrolment, year 3 and 5. Two HEp-2 indirect immunofluorescence assays (IFA1, IFA2), an ANA ELISA, and SLE-related autoantibodies were performed in one laboratory. Frequencies of positivity, titres or absorbance units (AU), and IFA patterns were compared using McNemar, Wilcoxon and kappa statistics, respectively.Results: At enrolment, ANA positivity (≥1:80) was 96.1% by IFA1 (median titre 1:1280 (IQR 1:640-1:5120)), 98.3% by IFA2 (1:2560 (IQR 1:640-1:5120)) and 96.6% by ELISA (176.3 AU (IQR 106.4 AU-203.5 AU)). At least one ANA assay was positive for 99.6% of patients at enrolment. At year 5, ANA positivity by IFAs (IFA1 95.2%; IFA2 98.9%) remained high, while there was a decrease in ELISA positivity (91.3%, p<0.001). Overall, there was >91% agreement in ANA positivity at all time points and ≥71% agreement in IFA patterns between IFA1 and IFA2.Conclusion: In recent-onset SLE, three ANA assays demonstrated commutability with a high proportion of positivity and titres or AU. However, over 5 years follow-up, there was modest variation in ANA assay performance. In clinical situations where the SLE diagnosis is being considered, a negative test by either the ELISA or HEp-2 IFA may require reflex testing. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

24. Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis

Author

Colaco, Keith, primary, Lee, Ker-Ai, additional, Akhtari, Shadi, additional, Winer, Raz, additional, Welsh, Paul, additional, Sattar, Naveed, additional, McInnes, Iain B, additional, Chandran, Vinod, additional, Harvey, Paula, additional, Cook, Richard J, additional, Gladman, Dafna D, additional, Piguet, Vincent, additional, and Eder, Lihi, additional

Published
2021
Full Text
View/download PDF

27. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance

Author

Aringer, Martin, primary, Brinks, Ralph, additional, Dörner, Thomas, additional, Daikh, David, additional, Mosca, Marta, additional, Ramsey-Goldman, Rosalind, additional, Smolen, Josef S, additional, Wofsy, David, additional, Boumpas, Dimitrios T, additional, Kamen, Diane L, additional, Jayne, David, additional, Cervera, R, additional, Costedoat-Chalumeau, Nathalie, additional, Diamond, Betty, additional, Gladman, Dafna D, additional, Hahn, Bevra, additional, Hiepe, Falk, additional, Jacobsen, Søren, additional, Khanna, Dinesh, additional, Lerstrøm, Kirsten, additional, Massarotti, Elena, additional, McCune, Joseph, additional, Ruiz-Irastorza, Guillermo, additional, Sanchez-Guerrero, Jorge, additional, Schneider, Matthias, additional, Urowitz, Murray, additional, Bertsias, George, additional, Hoyer, Bimba F, additional, Leuchten, Nicolai, additional, Schmajuk, Gabriela, additional, Tani, Chiara, additional, Tedeschi, Sara K, additional, Touma, Zahi, additional, Anic, Branimir, additional, Assan, Florence, additional, Chan, Tak Mao, additional, Clarke, Ann Elaine, additional, Crow, Mary K, additional, Czirják, László, additional, Doria, Andrea, additional, Graninger, Winfried, additional, Halda-Kiss, Bernadett, additional, Hasni, Sarfaraz, additional, Izmirly, Peter M, additional, Jung, Michelle, additional, Kumánovics, Gábor, additional, Mariette, Xavier, additional, Padjen, Ivan, additional, Pego-Reigosa, José M, additional, Romero-Diaz, Juanita, additional, Rúa-Figueroa, Íñigo, additional, Seror, Raphaèle, additional, Stummvoll, Georg H, additional, Tanaka, Yoshiya, additional, Tektonidou, Maria G, additional, Vasconcelos, Carlos, additional, Vital, Edward M, additional, Wallace, Daniel J, additional, Yavuz, Sule, additional, Meroni, Pier Luigi, additional, Fritzler, Marvin J, additional, Naden, Ray, additional, Costenbader, Karen, additional, and Johnson, Sindhu R, additional

Published
2021
Full Text
View/download PDF

31. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort

Author

Parker, Ben, Urowitz, Murray B, Gladman, Dafna D, Lunt, Mark, Bae, Sang-Cheol, Sanchez-Guerrero, Jorge, Romero-Diaz, Juanita, Gordon, Caroline, Wallace, Daniel J, Clarke, Ann E, Bernatsky, Sasha, Ginzler, Ellen M, Isenberg, David A, Rahman, Anisur, Merrill, Joan T, Alarcón, Graciela S, Fessler, Barri J, Fortin, Paul R, Hanly, John G, Petri, Michelle, Steinsson, Kristjan, Dooley, Mary-Anne, Manzi, Susan, Khamashta, Munther A, Ramsey-Goldman, Rosalind, Zoma, Asad A, Sturfelt, Gunnar K, Nived, Ola, Aranow, Cynthia, Mackay, Meggan, Ramos-Casals, Manuel, van Vollenhoven, Raymond F, Kalunian, Kenneth C, Ruiz-Irastorza, Guillermo, Lim, Sam, Kamen, Diane L, Peschken, Christine A, Inanc, Murat, and Bruce, Ian N

Published
2013
Full Text
View/download PDF

32. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

Author

Johnson, Sindhu R, primary, Brinks, Ralph, additional, Costenbader, Karen H, additional, Daikh, David, additional, Mosca, Marta, additional, Ramsey-Goldman, Rosalind, additional, Smolen, Josef S, additional, Wofsy, David, additional, Boumpas, Dimitrios T, additional, Kamen, Diane L, additional, Jayne, David, additional, Cervera, R, additional, Costedoat-Chalumeau, Nathalie, additional, Diamond, Betty, additional, Gladman, Dafna D, additional, Hahn, Bevra, additional, Hiepe, Falk, additional, Jacobsen, Søren, additional, Khanna, Dinesh, additional, Lerstrøm, Kirsten, additional, Massarotti, Elena, additional, McCune, Joseph, additional, Ruiz-Irastorza, Guillermo, additional, Sanchez-Guerrero, Jorge, additional, Schneider, Matthias, additional, Urowitz, Murray, additional, Bertsias, George, additional, Hoyer, Bimba F, additional, Leuchten, Nicolai, additional, Tani, Chiara, additional, Tedeschi, Sara K, additional, Touma, Zahi, additional, Schmajuk, Gabriela, additional, Anic, Branimir, additional, Assan, Florence, additional, Chan, Tak Mao, additional, Clarke, Ann Elaine, additional, Crow, Mary K, additional, Czirják, László, additional, Doria, Andrea, additional, Graninger, Winfried B, additional, Halda-Kiss, Bernadett, additional, Hasni, Sarfaraz, additional, Izmirly, Peter M, additional, Jung, Michelle, additional, Kumánovics, Gábor, additional, Mariette, Xavier, additional, Padjen, Ivan, additional, Pego-Reigosa, José M, additional, Romero-Diaz, Juanita, additional, Rúa-Figueroa, Íñigo, additional, Seror, Raphaèle, additional, Stummvoll, Georg H, additional, Tanaka, Yoshiya, additional, Tektonidou, Maria G, additional, Vasconcelos, Carlos, additional, Vital, Edward M, additional, Wallace, D J, additional, Yavuz, Sule, additional, Meroni, Pier Luigi, additional, Fritzler, Marvin J, additional, Naden, Ray, additional, Dörner, Thomas, additional, and Aringer, Martin, additional

Published
2020
Full Text
View/download PDF

33. Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics

Author

Mendel, Arielle, primary, Bernatsky, Sasha, additional, Askanase, Anca, additional, Bae, Sang-Cheol, additional, Clarke, Ann Elaine, additional, Costedoat-Chalumeau, Nathalie, additional, Gladman, Dafna D, additional, Gordon, Caroline, additional, Hanly, John, additional, Jacobsen, Søren, additional, Kalunian, Ken, additional, Mak, Anselm, additional, Mosca, Marta, additional, Pons-Estel, Bernardo A, additional, Ruiz-Irastorza, Guillermo, additional, Urowitz, Murray, additional, and Vinet, Évelyne, additional

Published
2020
Full Text
View/download PDF

35. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach

Author

Hanly, John G, primary, Urowitz, Murray B, additional, Gordon, Caroline, additional, Bae, Sang-Cheol, additional, Romero-Diaz, Juanita, additional, Sanchez-Guerrero, Jorge, additional, Bernatsky, Sasha, additional, Clarke, Ann E, additional, Wallace, Daniel J, additional, Isenberg, David A, additional, Rahman, Anisur, additional, Merrill, Joan T, additional, Fortin, Paul R, additional, Gladman, Dafna D, additional, Bruce, Ian N, additional, Petri, Michelle, additional, Ginzler, Ellen M, additional, Dooley, Mary Anne, additional, Ramsey-Goldman, Rosalind, additional, Manzi, Susan, additional, Jönsen, Andreas, additional, Alarcón, Graciela S, additional, van Vollenhoven, Ronald F, additional, Aranow, Cynthia, additional, Mackay, Meggan, additional, Ruiz-Irastorza, Guillermo, additional, Lim, Sam, additional, Inanc, Murat, additional, Kalunian, Kenneth C, additional, Jacobsen, Søren, additional, Peschken, Christine A, additional, Kamen, Diane L, additional, Askanase, Anca, additional, and Farewell, Vernon, additional

Published
2020
Full Text
View/download PDF

39. New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE.

Author

Garcia, Laura P. Whittall, Gladman, Dafna D., Urowitz, Murray, Touma, Zahi, Jiandong Su, Johnson, Sindhu R., Whittall Garcia, Laura P, and Su, Jiandong

Abstract

Objective: To determine the ominosity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Systemic Lupus Erythematosus Classification Criteria by determining its predictive role for disease severity in the first 5 years following diagnosis.Methods: 867 patients with systemic lupus erythematosus (SLE) from the Toronto Lupus Clinic were included (all first 12 months after SLE diagnosis). The EULAR/ACR criteria score was calculated based on baseline information. To determine disease severity in the first 5 years after diagnosis, adjusted mean SLE Disease Activity Index 2000 (AMS), flares, remission and immunosuppressive treatment were used as outcomes. The Systemic Lupus International Collaborating Clinics (SLICC) registry comprised the validation cohort.Results: Based on receiver operating characteristic analysis, a EULAR/ACR score of 20 was used as a threshold to compare outcomes between groups. In the first 5 years of disease course, patients with a score of ≥20 had higher AMS scores (p<0.001) and were more likely to ever experience a flare (p<0.001). These patients had lower probabilities of achieving remission and higher requirements for immunosuppressives. Results were confirmed in the SLICC validation cohort. Patients with a score of ≥20 had higher AMS during the first 5 years of disease (5.4 vs 3.1% and ≥20 vs <20 respectively, p≤0.001). The score correlated with AMS (r=0.43, p≤0.001) in the same time frame.Conclusion: A EULAR/ACR score of ≥20 is an indicator of ominosity in SLE. Patients with a score of ≥20 were characterised by a more active disease course throughout the first 5 years. These criteria provide prognostic information regarding disease severity in the first 5 years following diagnosis. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

41. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

Author

Aringer, Martin, primary, Costenbader, Karen, additional, Daikh, David, additional, Brinks, Ralph, additional, Mosca, Marta, additional, Ramsey-Goldman, Rosalind, additional, Smolen, Josef S, additional, Wofsy, David, additional, Boumpas, Dimitrios T, additional, Kamen, Diane L, additional, Jayne, David, additional, Cervera, Ricard, additional, Costedoat-Chalumeau, Nathalie, additional, Diamond, Betty, additional, Gladman, Dafna D, additional, Hahn, Bevra, additional, Hiepe, Falk, additional, Jacobsen, Søren, additional, Khanna, Dinesh, additional, Lerstrøm, Kirsten, additional, Massarotti, Elena, additional, McCune, Joseph, additional, Ruiz-Irastorza, Guillermo, additional, Sanchez-Guerrero, Jorge, additional, Schneider, Matthias, additional, Urowitz, Murray, additional, Bertsias, George, additional, Hoyer, Bimba F, additional, Leuchten, Nicolai, additional, Tani, Chiara, additional, Tedeschi, Sara K, additional, Touma, Zahi, additional, Schmajuk, Gabriela, additional, Anic, Branimir, additional, Assan, Florence, additional, Chan, Tak Mao, additional, Clarke, Ann Elaine, additional, Crow, Mary K, additional, Czirják, László, additional, Doria, Andrea, additional, Graninger, Winfried, additional, Halda-Kiss, Bernadett, additional, Hasni, Sarfaraz, additional, Izmirly, Peter M, additional, Jung, Michelle, additional, Kumánovics, Gábor, additional, Mariette, Xavier, additional, Padjen, Ivan, additional, Pego-Reigosa, José M, additional, Romero-Diaz, Juanita, additional, Rúa-Figueroa Fernández, Íñigo, additional, Seror, Raphaèle, additional, Stummvoll, Georg H, additional, Tanaka, Yoshiya, additional, Tektonidou, Maria G, additional, Vasconcelos, Carlos, additional, Vital, Edward M, additional, Wallace, Daniel J, additional, Yavuz, Sule, additional, Meroni, Pier Luigi, additional, Fritzler, Marvin J, additional, Naden, Ray, additional, Dörner, Thomas, additional, and Johnson, Sindhu R, additional

Published
2019
Full Text
View/download PDF

45. Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort

Author

Mendel, Arielle, primary, Bernatsky, Sasha B, additional, Hanly, John G, additional, Urowitz, Murray B, additional, Clarke, Ann Elaine, additional, Romero-Diaz, Juanita, additional, Gordon, Caroline, additional, Bae, Sang-Cheol, additional, Wallace, Daniel J, additional, Merrill, Joan T, additional, Buyon, Jill P, additional, Isenberg, David A, additional, Rahman, Anisur, additional, Ginzler, Ellen M, additional, Petri, Michelle, additional, Dooley, Mary Anne, additional, Fortin, Paul R, additional, Gladman, Dafna D, additional, Steinsson, Kristján, additional, Ramsey-Goldman, Rosalind, additional, Khamashta, Munther A, additional, Aranow, Cynthia, additional, Mackay, Meggan, additional, Alarcón, Graciela S, additional, Manzi, Susan, additional, Nived, Ola, additional, Jönsen, Andreas, additional, Zoma, Asad A, additional, van Vollenhoven, Ronald F, additional, Ramos-Casals, Manuel, additional, Ruiz-Irastorza, Guillermo, additional, Lim, Sam, additional, Kalunian, Ken C, additional, Inanc, Murat, additional, Kamen, Diane L, additional, Peschken, Christine A, additional, Jacobsen, Søren, additional, Askanase, Anca, additional, Sanchez-Guerrero, Jorge, additional, Bruce, Ian N, additional, Costedoat-Chalumeau, Nathalie, additional, and Vinet, Évelyne, additional

Published
2018
Full Text
View/download PDF

46. Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'.

Author

Gladman, Dafna D., Mease, Philip J., Bird, Paul, Soriano, Enrique R., Chakravarty, Soumya D., Shawi, May, Lavie, Frederic, Gong, Cinty, Leibowitz, Evan, Poddubnyy, Denis, Lai-Shan Tam, Helliwell, Philip S., Kavanaugh, Arthur, Deodhar, Atul A., Østergaard, Mikkel, and Baraliakos, Xenofon

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results